ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zeta
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Solid Cancer Metastatic Disease
Conditions
Solid Cancer Metastatic Disease, Lymphoid Disease
Trial Timeline
Apr 1, 2013 → Nov 1, 2014
NCT ID
NCT02213653About ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zeta
ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zeta is a approved stage product being developed by Roche for Solid Cancer Metastatic Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02213653. Target conditions include Solid Cancer Metastatic Disease, Lymphoid Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02213653 | Approved | Terminated |
Competing Products
20 competing products in Solid Cancer Metastatic Disease